ADVANCES IN THE DIAGNOSIS AND MANAGEMENT OF MYASTHENIA GRAVIS

Dinora Abduraimova; Saida Qosimova; Karima Abduaxatova; Bahora Khamdamova

Vol. 4 No. 6 (2026), Articles

Vol. 4 No. 6 (2026)

ADVANCES IN THE DIAGNOSIS AND MANAGEMENT OF MYASTHENIA GRAVIS

Articles

Published 2026-07-05

Dinora Abduraimova⁺⁻
Saida Qosimova⁺⁻
Karima Abduaxatova⁺⁻
Bahora Khamdamova⁺⁻

Dinora Abduraimova

2nd-Year Resident, Department of Neurology, Faculty of Postgraduate Medical Education, Samarkand State Medical University

Saida Qosimova

2nd-Year Resident, Department of Neurology, Faculty of Postgraduate Medical Education, Samarkand State Medical University

Karima Abduaxatova

2nd-Year Resident, Department of Neurology, Faculty of Postgraduate Medical Education, Samarkand State Medical University

Bahora Khamdamova

Scientific Supervisor: Assistant, Department of Neurology, Faculty of Postgraduate Medical Education, Samarkand State Medical University

PDF

DOI

Keywords

Myasthenia gravis
autoimmune disease
neuromuscular junction
acetylcholine receptor antibodies
diagnosis

How to Cite

ADVANCES IN THE DIAGNOSIS AND MANAGEMENT OF MYASTHENIA GRAVIS. (2026). "XXI ASRDA INNOVATSION TEXNOLOGIYALAR, FAN VA TAʼLIM TARAQQIYOTIDAGI DOLZARB MUAMMOLAR" Nomli Respublika Ilmiy-Amaliy Konferensiyasi, 4(6), 279-283. https://universalpublishings.com/index.php/itfttdm/article/view/20007

Abstract

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness and fatigue caused by impaired transmission at the neuromuscular junction. The disease is most commonly associated with antibodies directed against acetylcholine receptors or other postsynaptic membrane proteins. Recent advances in immunology, neurophysiology, and molecular diagnostics have significantly improved the early detection and management of myasthenia gravis. Modern therapeutic approaches, including immunosuppressive agents, monoclonal antibodies, thymectomy, and individualized treatment strategies, have contributed to better clinical outcomes and quality of life for patients. This article reviews current developments in the diagnosis and management of myasthenia gravis, highlighting recent innovations and future perspectives in patient care.

PDF

DOI

References

1. Gilhus NE. Myasthenia Gravis. New England Journal of Medicine. 2016;375(26):2570–2581.

2. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114–122.

3. Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia Gravis. Nature Reviews Disease Primers. 2019;5(1):30.

4. Verschuuren JJGM, Palace J, Murai H, et al. Advances in the Treatment of Myasthenia Gravis. Lancet Neurology. 2022;21(6):540–552.

5. Sanders DB, Wolfe GI, Benatar M, et al. International Consensus Guidance for Management of Myasthenia Gravis. Neurology. 2016;87(4):419–425.

6. Lazaridis K, Tzartos SJ. Autoantibody Specificities in Myasthenia Gravis. Frontiers in Neurology. 2020;11:212.

7. Howard JF Jr. Myasthenia Gravis: The Role of Complement at the Neuromuscular Junction. Annals of the New York Academy of Sciences. 2018;1412(1):113–128.

8. Mantegazza R, Antozzi C. When Myasthenia Gravis Is Diagnosed: Clinical Features and Treatment Options. Autoimmunity Reviews. 2018;17(7):703–708.

9. Evoli A, Alboini PE, Damato V, et al. Management Challenges in Muscle-Specific Kinase Myasthenia Gravis. Annals of the New York Academy of Sciences. 2018;1413(1):41–46.

10. Gilhus NE, Verschuuren JJ. Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies. Lancet Neurology. 2015;14(10):1023–1036.